Thrombocythaemia Myelofibrosis - Pipeline Review, H2 2016

  • ID: 3821701
  • Report
  • 55 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Celgene Corporation
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • Nippon Shinyaku Co., Ltd.
  • Novartis AG
  • Pfizer Inc.
  • MORE
Thrombocythaemia Myelofibrosis - Pipeline Review, H2 2016

Summary

‘Thrombocythaemia Myelofibrosis - Pipeline Review, H2 2016’, provides an overview of the Thrombocythaemia Myelofibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Thrombocythaemia Myelofibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thrombocythaemia Myelofibrosis and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Thrombocythaemia Myelofibrosis
- The report reviews pipeline therapeutics for Thrombocythaemia Myelofibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Thrombocythaemia Myelofibrosis therapeutics and enlists all their major and minor projects
- The report assesses Thrombocythaemia Myelofibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Thrombocythaemia Myelofibrosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Thrombocythaemia Myelofibrosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Thrombocythaemia Myelofibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Celgene Corporation
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • Nippon Shinyaku Co., Ltd.
  • Novartis AG
  • Pfizer Inc.
  • MORE
List of Figures

Introduction

Report Coverage

Thrombocythaemia Myelofibrosis Overview

Therapeutics Development

Pipeline Products for Thrombocythaemia Myelofibrosis - Overview

Pipeline Products for Thrombocythaemia Myelofibrosis - Comparative Analysis

Thrombocythaemia Myelofibrosis - Therapeutics under Development by Companies

Thrombocythaemia Myelofibrosis - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Thrombocythaemia Myelofibrosis - Products under Development by Companies

Thrombocythaemia Myelofibrosis - Companies Involved in Therapeutics Development

Celgene Corporation

Gilead Sciences, Inc.

Incyte Corporation

JW Pharmaceutical Corporation

Nippon Shinyaku Co., Ltd.

Novartis AG

Pfizer Inc.

Thrombocythaemia Myelofibrosis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

buparlisib hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CWP-291 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glasdegib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

itacitinib adipate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

momelotinib dihydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NS-018 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pomalidomide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Thrombocythaemia Myelofibrosis - Dormant Projects

Thrombocythaemia Myelofibrosis - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Thrombocythaemia Myelofibrosis, H2 2016

Number of Products under Development for Thrombocythaemia Myelofibrosis - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Products under Development by Companies, H2 2016

Thrombocythaemia Myelofibrosis - Pipeline by Celgene Corporation, H2 2016

Thrombocythaemia Myelofibrosis - Pipeline by Gilead Sciences, Inc., H2 2016

Thrombocythaemia Myelofibrosis - Pipeline by Incyte Corporation, H2 2016

Thrombocythaemia Myelofibrosis - Pipeline by JW Pharmaceutical Corporation, H2 2016

Thrombocythaemia Myelofibrosis - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016

Thrombocythaemia Myelofibrosis - Pipeline by Novartis AG, H2 2016

Thrombocythaemia Myelofibrosis - Pipeline by Pfizer Inc., H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Thrombocythaemia Myelofibrosis - Dormant Projects, H2 2016

Thrombocythaemia Myelofibrosis - Discontinued Products, H2 2016 53List of Figures

Number of Products under Development for Thrombocythaemia Myelofibrosis, H2 2016

Number of Products under Development for Thrombocythaemia Myelofibrosis - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Celgene Corporation
Gilead Sciences, Inc.
Incyte Corporation
JW Pharmaceutical Corporation
Nippon Shinyaku Co., Ltd.
Novartis AG
Pfizer Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll